Showing results (211-220 of 302) with videos related to

Sort By:
Pageof 31
Blood|March 16, 2025
Blunted CD40-responsive enhancer activation in CREBBP-mutant lymphomas can be restored by enforced CD4 T-cell engagementHaopeng Yang, Wenchao Zhang, Vida Ravanmehr, et al.
Blood|April 16, 2008
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximabIssa F Khouri, Peter McLaughlin, Rima M Saliba, et al.
The Lancet. Oncology|December 17, 2013
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trialJason R Westin, Fuliang Chu, Min Zhang, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2014
Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trialYasuhiro Oki, Michael S Ewer, Daniel J Lenihan, et al.
Plos One|March 15, 2018
The risk of central nervous system relapses in patients with peripheral T-cell lymphomaDai Chihara, Michelle A Fanale, Roberto N Miranda, et al.
Blood|April 8, 2014
Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLLPaolo Strati, Michael J Keating, Susan M O'Brien, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 7, 2025
Perspectives on Current Challenges and Emerging Approaches for Lymphoma Management From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma ConferenceAlexey V Danilov, Craig Sauter, Tycel Phillips, et al.
Leukemia & Lymphoma|December 17, 2020
Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclaxMario L Marques-Piubelli, Ellen J Schlette, Joseph D Khoury, et al.
Annals of Hematology|March 2, 2017
Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractionsPaolo Strati, Prithviraj Bose, Lindsey Lyle, et al.
Cancer|October 24, 2013
HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemiaPaolo Strati, Hagop Kantarjian, Deborah Thomas, et al.
Pageof 31